Clinical trials in womens cancers

女性癌症的临床试验

• 批准号: 10926247
• 负责人: Christina Annunziata
• 金额: $ 39.18万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10926247
• 关键词: BAY 54-9085; BRCA mutations; Blood; Clinic; Clinical Data; Clinical Trials; Collaborations; Dasatinib; Development; Enrollment; Goals; Growth Factor; Hereditary Breast and Ovarian Cancer Syndrome; Induction of Apoptosis; Institutional Review Boards; International; Karyotype; Li-Fraumeni Syndrome; Malignant Neoplasms; Malignant neoplasm of ovary; Metabolic; Metformin; Patients; Peritoneal; Phase; Pleural; Pregnant Women; Process; Protein Family; Protocols documentation; Research Personnel; Source; Specimen; Testing; Therapeutic; Woman; angiogenesis; bevacizumab; drug testing; effusion; fetal; inhibitor-of-apoptosis protein; phase 1 study; prevent

We are currently in the process of analyzing specimens and data from clinical trials 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; and 09-C-0019 phase 1 study of bevacizumab and dasatinib. As a Branch, we opened 19-C-0025 to collect blood and effusions (pleural and peritoneal) from patients with cancer enrolled on other protocols at the NCI. Additional clinical trials are under development at the concept stage or are under review by IRB. Within the WMB, I collaborate with Jung-min Lee and Stan Lipkowitz as Associate Investigator on several other clinical trials. I also collaborate with Diana Bianchi on a clinical trial to investigate the source of abnormal cfDNA in pregnant women with normal fetal karyotype. Another collaboration tested the metabolic effects of metformin in patients with Li Fraumeni Syndrome, and a larger international clinical trial is under development to test this drug as a strategy to prevent cancer in LFS patients.

我们目前正在分析卵巢癌临床试验07C0058-贝伐单抗和索拉非尼2期的样本和数据，以及09-C-0019贝伐单抗和达沙替尼的1期研究。作为一个分支机构，我们开设了19-C-0025，从NCI登记的其他方案的癌症患者身上收集血液和积液(胸腔和腹膜)。其他临床试验正在概念阶段开发中，或正在接受IRB的审查。在WMB内部，我与李正民和斯坦·利普科维茨合作，担任其他几项临床试验的副研究员。我还与戴安娜·比安奇合作进行了一项临床试验，以调查胎儿核型正常的孕妇cfDNA异常的来源。另一项合作测试了二甲双胍对Li Fraumeni综合征患者的代谢影响，一项更大规模的国际临床试验正在开发中，以测试这种药物作为预防LFS患者癌症的策略。

项目成果

Clinical trials in gynecologic oncology: Past, present, and future.

妇科肿瘤学临床试验：过去、现在和未来。

• DOI: 10.1016/j.ygyno.2017.11.026
• 发表时间: 2018
• 期刊: Gynecologic oncology
• 影响因子: 4.7
• 作者: Annunziata,ChristinaM;Kohn,EliseC
• 通讯作者: Kohn,EliseC

Prenatal DNA Sequencing for Fetal Aneuploidy Also Detects Maternal Cancer: Importance of Timely Workup and Management in Pregnant Women.

• DOI: 10.1200/jco.22.00733
• 发表时间: 2022-06
• 期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• 作者: Amy E Turriff;C. Annunziata;D. Bianchi

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.

ONC201 治疗复发/难治性转移性乳腺癌和晚期子宫内膜癌的单臂、开放标签 II 期研究。

• DOI: 10.1093/oncolo/oyad164
• 发表时间: 2023
• 期刊: The oncologist
• 作者: Atkins,SarahLP;Greer,YoshimiEndo;Jenkins,Sarah;Gatti-Mays,MargaretE;Houston,Nicole;Lee,Sunmin;Lee,Min-Jung;Rastogi,Shraddha;Sato,Nahoko;Burks,Christina;Annunziata,ChristinaM;Lee,Jung-Min;Nagashima,Kunio;Trepel,JaneB;Lipko
• 通讯作者: Lipko

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas.

• DOI: 10.3390/cancers14133037
• 发表时间: 2022-06-21
• 期刊: CANCERS
• 影响因子: 5.2
• 作者: Tsang, Kwong Yok;Fantini, Massimo;Mavroukakis, Sharon A.;Zaki, Anjum;Annunziata, Christina M.;Arlen, Philip M.
• 通讯作者: Arlen, Philip M.

Editorial: Inhibiting PARP as a Strategic Target in Cancer.

社论：抑制 PARP 作为癌症的战略目标。

• DOI: 10.3389/fonc.2016.00091
• 发表时间: 2016
• 期刊: Frontiers in oncology
• 影响因子: 4.7
• 作者: Zorn,KristinK;Annunziata,ChristinaM
• 通讯作者: Annunziata,ChristinaM